Acute Effects of Rhodiola Rosea and Caffeine on Mean Propulsive Velocity Loss in Resistance Training
NCT07924020, Not applicable, Not yet recruiting, MARINA MEDINA CORRALES
Trial 10
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
| Field | Value | Source |
|---|---|---|
| Title | Acute Effects of Rhodiola Rosea and Caffeine on Mean Propulsive Velocity Loss in Resistance Training | ClinicalTrials.gov |
| NCT number | NCT07924020 | ClinicalTrials.gov |
| Status | Not yet recruiting | ClinicalTrials.gov |
| Phases | Not applicable | ClinicalTrials.gov |
| Enrollment | 20 participants, estimated | ClinicalTrials.gov |
| Lead sponsor | MARINA MEDINA CORRALES | ClinicalTrials.gov |
| Conditions | Muscle Fatigue (C23.888.592.612.612) | ClinicalTrials.gov |
| Interventions | Rhodiola Rosea Capsules, Caffeine, Rhodiola Placebo, Caffeine Placebo | ClinicalTrials.gov |
| First posted | 2026-11-09 | ClinicalTrials.gov |
| Last updated | 2026-11-09 | ClinicalTrials.gov |
Registered outcomes 3
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description | Source |
|---|---|---|---|---|
| Primary | Percentage Loss in Mean Propulsive Velocity (MPV) | Baseline (pre-fatigue), 1 minute, and 2 minutes post-fatiguing exercise protocol, up to 2 weeks. | Percentage loss in mean propulsive velocity (MPV) following the fatiguing protocol. MPV is assessed during the barbell back squat using an individualized load corresponding to an initial velocity of 1.0 ± 0.03 m/s, recorded via a linear position transducer. Percentage loss is calculated relative to pre-fatigue baseline as: \[(baseline MPV - post-fatigue MPV) / baseline MPV\] × 100. The fatiguing protocol consists of 3 sets to failure at 70% 1RM. | ClinicalTrials.gov |
| Secondary | Total Number of Repetitions to Failure | Immediately upon completion of the fatiguing exercise protocol, up to 2 weeks | Cumulative number of successful repetitions completed across 3 sets at 70% 1RM performed to momentary muscular failure during the fatiguing protocol. Data are reported as the total number of repetitions completed per experimental condition. | ClinicalTrials.gov |
| Secondary | Rating of Perceived Exertion (RPE) | Immediately, 1 minute, and 2 minutes post-fatiguing exercise protocol, up to 2 weeks | Subjective perception of effort assessed using a standardized RPE scale immediately following the fatiguing protocol to quantify internal load. | ClinicalTrials.gov |
Outcomes 0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as | Source |
|---|
Results by group 0
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units | Source |
|---|
Participant flow 0
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted | Source |
|---|
Adverse events 0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events | Source |
|---|
Adverse event totals 0
The totals the trial posted for each group.
| Total | Group | Affected | At risk | Source |
|---|
Papers 0
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as | Source |
|---|
Grants 0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years | Source |
|---|
Trial comparisons 0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|
Tests 0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|
Source 5
| Field | Value | Source |
|---|---|---|
| Release | trials-2026-11-12-0.4.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4 | ClinicalTrials.gov |
| Registry capture | 2026-11-12 | ClinicalTrials.gov |
| Results copy, AACT | 2026-03-23 | ClinicalTrials.gov |
| NIH clinical studies file | 2026-11-13 | ClinicalTrials.gov |
Release trials-2026-11-12-0.4.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
NIH RePORTER's clinical studies and project files: Public domain (NIH RePORTER)